RDHL — Redhill Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00- $7.15m
- $2.75m
- $6.53m
- 40
- 91
- 16
- 46
Annual cashflow statement for Redhill Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -42.3 | -76.2 | -97.7 | -71.7 | 23.9 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 2.68 | 10.4 | 15.7 | 26.3 | -46.1 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2.34 | 8.42 | -1.15 | 8.01 | -15.6 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -40.7 | -48.6 | -65 | -29.2 | -35.8 |
| Capital Expenditures | -0.203 | -53.8 | -0.115 | -0.198 | -0.011 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 5.37 | 18.1 | -8.03 | 8.5 | 0.015 |
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 5.16 | -35.6 | -8.14 | 8.3 | 0.004 |
| Financing Cash Flow Items | 0 | -16 | -7.4 | -10.9 | 8.65 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 35.5 | 84.4 | 73.5 | 11.5 | 21.4 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.018 | 0.272 | 0.179 | -9.51 | -14.4 |